Name | Number of supported studies | Average coverage | |
---|---|---|---|
ciliated cell | 3 studies | 19% ± 2% |
Insufficient scRNA-seq data for expression of SPSB2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 770.55 | 653 / 653 | 100% | 26.25 | 604 / 605 |
uterus | 100% | 438.90 | 170 / 170 | 99% | 16.87 | 455 / 459 |
brain | 99% | 238.90 | 2622 / 2642 | 100% | 15.85 | 703 / 705 |
adrenal gland | 100% | 625.53 | 258 / 258 | 99% | 13.65 | 227 / 230 |
ovary | 100% | 287.73 | 180 / 180 | 99% | 14.33 | 424 / 430 |
kidney | 100% | 699.76 | 89 / 89 | 98% | 18.08 | 885 / 901 |
lung | 100% | 788.82 | 577 / 578 | 98% | 24.62 | 1133 / 1155 |
intestine | 100% | 409.87 | 966 / 966 | 98% | 14.86 | 516 / 527 |
pancreas | 98% | 268.52 | 322 / 328 | 99% | 20.85 | 177 / 178 |
skin | 100% | 428.46 | 1809 / 1809 | 97% | 13.54 | 460 / 472 |
bladder | 100% | 432.14 | 21 / 21 | 97% | 18.09 | 491 / 504 |
prostate | 100% | 445.70 | 245 / 245 | 96% | 10.49 | 484 / 502 |
esophagus | 100% | 365.07 | 1445 / 1445 | 96% | 11.52 | 175 / 183 |
stomach | 99% | 353.06 | 357 / 359 | 96% | 13.21 | 274 / 286 |
breast | 100% | 365.41 | 459 / 459 | 95% | 13.70 | 1064 / 1118 |
liver | 98% | 211.65 | 222 / 226 | 92% | 12.41 | 375 / 406 |
eye | 0% | 0 | 0 / 0 | 100% | 16.48 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 21.14 | 29 / 29 |
spleen | 100% | 548.71 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 15.48 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 21.72 | 1 / 1 |
blood vessel | 100% | 425.34 | 1334 / 1335 | 0% | 0 | 0 / 0 |
adipose | 100% | 318.86 | 1202 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 98% | 282.24 | 907 / 929 | 0% | 0 | 0 / 0 |
heart | 94% | 167.43 | 807 / 861 | 0% | 0 | 0 / 0 |
muscle | 85% | 120.85 | 685 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006511 | Biological process | ubiquitin-dependent protein catabolic process |
GO_0016567 | Biological process | protein ubiquitination |
GO_0035556 | Biological process | intracellular signal transduction |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0019005 | Cellular component | SCF ubiquitin ligase complex |
GO_0005829 | Cellular component | cytosol |
GO_1990756 | Molecular function | ubiquitin-like ligase-substrate adaptor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | SPSB2 |
Protein name | SPRY domain-containing SOCS box protein 2 (SSB-2) (Gene-rich cluster protein C9) SplA/ryanodine receptor domain and SOCS box containing 2 |
Synonyms | GRCC9 SSB2 |
Description | FUNCTION: Substrate recognition component of a SCF-like ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins . Negatively regulates nitric oxide (NO) production and limits cellular toxicity in activated macrophages by mediating the ubiquitination and proteasomal degradation of NOS2 . Acts as a bridge which links NOS2 with the ECS E3 ubiquitin ligase complex components ELOC and CUL5 . . |
Accessions | ENST00000524270.6 [Q99619-1] ENST00000432205.5 ENST00000523102.5 [Q99619-1] ENST00000519357.1 [Q99619-2] Q99619 E5RIC2 |